MacroGenics to Participate in Upcoming Investor Conference

MGNX 12.02.2024

Full Press ReleaseSEC FilingsOur MGNX Tweets

About Gravity Analytica

Recent News

  • 01.03.2025 - Beth Smith
  • 12.04.2024 - 7th Annual Evercore HealthCONx (Coral Gables, FL)
  • 12.02.2024 - MacroGenics to Participate in Upcoming Investor Conference

Recent Filings

  • 01.13.2025 - 3 Initial statement of beneficial ownership of securities
  • 11.21.2024 - 8-K Current report
  • 11.20.2024 - SC 13G Statement of Beneficial Ownership by Certain Investors
MacroGenics to Participate in Upcoming Investor Conference

ROCKVILLE, MD,Dec. 02, 2024(GLOBE NEWSWIRE) -- --MacroGenics, Inc.(Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conference this month:

  • 7th Annual Evercore HealthCONx (Coral Gables, FL).MacroGenics’ President and Chief Executive Officer,Scott Koenig, M.D., Ph.D., will participate in a fireside chat onWednesday, December 4, 2024, at7:30am ET. MacroGenics’ management will also participate in one-on-one meetings.

A webcast of the above presentation may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website athttp://ir.macrogenics.com/events.cfm. The Company will maintain an archived replay of this webcast on its website for 30 days.

AboutMacroGenics, Inc.

MacroGenics(the Company) is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination ofMacroGenics'technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website atwww.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.

###

CONTACTS:Jim Karrels, Senior Vice President, CFO1-301-251-5172,  info@macrogenics.com

Primary Logo

Source: MacroGenics, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com